Patents by Inventor Andrew Good

Andrew Good has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20260167645
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: October 16, 2025
    Publication date: June 18, 2026
    Inventors: Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald K. SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
  • Macrocyclic compounds, compositions, and methods of using thereof
    Patent number: 12649750
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Grant
    Filed: September 12, 2025
    Date of Patent: June 9, 2026
    Assignees: Sionna Therapeutics Inc., Genzyme Corporation
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Macrocyclic compounds, compositions, and methods of using thereof
    Patent number: 12624051
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Grant
    Filed: September 12, 2025
    Date of Patent: May 12, 2026
    Assignees: Genzyme Corporation, Sionna Therapeutics Inc.
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20260098032
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: May 15, 2025
    Publication date: April 9, 2026
    Inventors: Binh VU, Romyr DOMINIQUE, Hongju LI, Bruce FAHR, Andrew GOOD
  • Uses of p53 x-ray co-crystal structures
    Patent number: 12570645
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. Disclosed herein are compounds and methods to recover wild-type function of p53 mutants using x-ray co-crystal structures of mutant p53 and compounds of the disclosure. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: March 10, 2026
    Assignee: PMV Pharmaceuticals, Inc.
    Inventors: Binh Vu, Andrew Good
  • GPR6 INVERSE AGONISTS
    Publication number: 20260042755
    Abstract: Provided herein, is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Cy, Hy, X, Y, Ra, Rb, Rc, and Rd are defined herein as well as compositions and methods of use thereof.
    Type: Application
    Filed: August 10, 2023
    Publication date: February 12, 2026
    Inventors: Andrew GOOD, Michael WOOD, Vinod F. PATEL, Mark SYLVESTER, Alexandre LARIVEE, Tarek MOHAMED, Maksym DIACHENKO, David Fabian LEON-RAYO, Amol Pandharianath JADHAV, Shekhar Reddy DURUPALA, Lea CONSTANTINEAU-FORGET
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20260008786
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20260008785
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Methods and compounds for restoring mutant p53 function
    Patent number: 12428406
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: September 30, 2025
    Assignee: PMV PHARMACEUTICALS, INC.
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250248975
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: August 7, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Isoquinoline compounds and uses thereof
    Patent number: 12378249
    Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: August 5, 2025
    Assignee: Genentech, Inc.
    Inventors: Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Joy Alison Drobnick, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250197422
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250197420
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Naphthyridine compounds and uses thereof
    Patent number: 12297210
    Abstract: Naphthyridine compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: May 13, 2025
    Assignee: Genentech, Inc.
    Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20250026749
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Application
    Filed: July 19, 2024
    Publication date: January 23, 2025
    Applicant: Genzyme Corporation
    Inventors: Elyse BOURQUE, Mario A. CABRERA-SALAZAR, Cassandra CELATKA, Seng H. CHENG, Bradford HIRTH, Andrew GOOD, Katherine JANCSICS, John MARSHALL, Markus METZ, Ronald K. SCHEULE, Renato SKERLJ, Yibin XIANG, Zhong ZHAO, John LEONARD, Thomas NATOLI, Elina MAKINO, Herve HUSSON, Oxana BESKROVNAYA
  • CINNOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20240368170
    Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
    Type: Application
    Filed: July 10, 2024
    Publication date: November 7, 2024
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • INDOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20240279220
    Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: March 1, 2024
    Publication date: August 22, 2024
    Inventors: Junkai Liao, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Hurlbut, David Borcherding, Matthieu Barrague, Timothy Alan Gillespy, Alexandre Gross, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Markus Metz, Anatoly Ruvinsky, Claude Barberis
  • Glucosylceramide synthase inhibitors
    Patent number: 12060349
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) of the Formula I: represented by the following structural formula or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: August 13, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Elyse Bourque, Mario A. Cabrera-Salazar, Cassandra Celatka, Seng H. Cheng, Bradford Hirth, Andrew Good, Katherine Jancsics, John Marshall, Markus Metz, Ronald K. Scheule, Renato Skerlj, Yibin Xiang, Zhong Zhao, John Leonard, Thomas Natoli, Elina Makino, Herve Husson, Oxana Beskrovnaya
  • INDOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20240239784
    Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: March 1, 2024
    Publication date: July 18, 2024
    Inventors: Junkai Liao, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Hurlbut, David Borcherding, Matthieu Barrague, Timothy Alan Gillespy, Alexandre Gross, Thaddeus Nieduzak, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Markus Metz, Anatoly Ruvinsky, Michael Kothe
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20240043436
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: June 7, 2023
    Publication date: February 8, 2024
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good